Matsuda Masaru's Form 4 filing

Arcutis Biotherapeutics, Inc.ARQT · filed May 6, 2026

Accession no.: 0001798679-26-000002
Filed: May 6, 2026
Trade date: May 4, 2026
Filing delay: 2 days
Rule 10b5-1 plan: Checked

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market sales total $192.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Matsuda MasaruCIK 0001798679	Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
May 4, 2026	Common Stock	SSaleDisposed	−7,372	$23.27^F2	−$171,546.44	127,573	Direct
May 4, 2026	Common Stock	SSaleDisposed	−884	$23.61^F5	−$20,871.24	126,689	Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.1167 to $23.48, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.16 to $23.93, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Remarks

Reporting Person's title: EVP, Chief Legal Officer

Read the full filing on SEC EDGAR (opens in a new tab)